Table 1 6-month Progression-free survival and median overall survival for recurrent or metastatic malignant meningioma treated with systemic therapy
Authors | Year | Study type | Drug used | Grade III meningioma (#) | 6-month PFS (%) | Median OS (month) |
|---|---|---|---|---|---|---|
Mazza et al. [25] | 2016 | Phase II, prospective | Hydroxyurea | 8 | NA | 27.5 |
Mazza et al. [25] | 2016 | Phase II, prospective | Hydroxyurea + imatinib | 7 | NA | 6 |
Kaley et al. [26] | 2015 | Phase II, prospective | Sunitinib | 6 | 44 | 24.6 |
Simo et al. [20] | 2014 | Phase II, prospective | Octreotide | 4 | 44 | 18.7 |
Raizer et al. [23] | 2014 | Phase II, prospective | Valatanib | 8 | 37.5 | 23 |
Lou et al. [21] | 2012 | Retrospective | Bevacizumab | 3 | 87.5 | NA |